Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Management of recurrent sebaceous gland carcinoma
Eye ( IF 2.8 ) Pub Date : 2020-01-02 , DOI: 10.1038/s41433-019-0756-9 Lindsay A McGrath 1 , Zanna I Currie 1 , Hardeep Singh Mudhar 2 , Jennifer H Y Tan 1 , Sachin M Salvi 1
Eye ( IF 2.8 ) Pub Date : 2020-01-02 , DOI: 10.1038/s41433-019-0756-9 Lindsay A McGrath 1 , Zanna I Currie 1 , Hardeep Singh Mudhar 2 , Jennifer H Y Tan 1 , Sachin M Salvi 1
Affiliation
|
Objective To evaluate the incidence and management of recurrent periocular sebaceous gland carcinoma at a tertiary ocular oncology service in the United Kingdom. Methods This was a retrospective cohort study of 62 patients with sebaceous gland carcinoma treated between 2004 and 2017. A total of 10 eyes were treated for local recurrence. The following variables were recorded: age and sex of patient; tumour location, histological subtype; recurrence type; treatment and outcome. Results Of the 62 cases with eyelid SGC, 10 (16%) had recurrences during the study period and satisfied inclusion criteria. There were six (60%) females and four males in the recurrent group. The mean time interval between initial excision and tumour recurrence was 37 months (median 23 months; range 4 to 84 months). Four patients received cryotherapy to the lids and conjunctiva to control recurrent disease and two patients were treated with topical or intralesional chemotherapy. Four patients (40%) underwent orbital exenteration during the study period. Metastasis occurred in 20% over a mean follow-up of 113 months (median 106; range 47–184 months). Conclusions The risk factors for local recurrence of SGC after wide excision with paraffin section control were reported, and an approach to these recurrent lesions was proposed. The results of this study will help guide surgeons dealing with the medical and surgical conundrum of recurrent disease. The risk of recurrence is highest in the first 2 years after initial excision.
中文翻译：
复发性皮脂腺癌的治疗
目的 评估英国三级眼肿瘤服务中复发性眼周皮脂腺癌的发病率和治疗。方法对2004年至2017年间收治的62例皮脂腺癌患者进行回顾性队列研究，共10只眼因局部复发而接受治疗。记录以下变量：患者的年龄和性别；肿瘤部位、组织学亚型；复发型；治疗和结果。结果 62例眼睑SGC患者中，10例（16%）在研究期间复发，符合纳入标准。复发组中有六名 (60%) 女性和四名男性。初次切除和肿瘤复发之间的平均时间间隔为 37 个月（中位 23 个月；范围 4 至 84 个月）。四名患者接受了眼睑和结膜冷冻疗法以控制复发性疾病，两名患者接受了局部或病灶内化疗。在研究期间，四名患者（40%）接受了眼眶切除术。平均随访 113 个月（中位 106 个月；范围 47-184 个月），20% 的患者发生转移。结论 报告了石蜡切片控制广泛切除后 SGC 局部复发的危险因素，并提出了治疗这些复发病灶的方法。这项研究的结果将有助于指导外科医生应对复发性疾病的医疗和外科难题。初次切除后的头 2 年复发风险最高。
更新日期：2020-01-02
中文翻译：
复发性皮脂腺癌的治疗
目的 评估英国三级眼肿瘤服务中复发性眼周皮脂腺癌的发病率和治疗。方法对2004年至2017年间收治的62例皮脂腺癌患者进行回顾性队列研究，共10只眼因局部复发而接受治疗。记录以下变量：患者的年龄和性别；肿瘤部位、组织学亚型；复发型；治疗和结果。结果 62例眼睑SGC患者中，10例（16%）在研究期间复发，符合纳入标准。复发组中有六名 (60%) 女性和四名男性。初次切除和肿瘤复发之间的平均时间间隔为 37 个月（中位 23 个月；范围 4 至 84 个月）。四名患者接受了眼睑和结膜冷冻疗法以控制复发性疾病，两名患者接受了局部或病灶内化疗。在研究期间，四名患者（40%）接受了眼眶切除术。平均随访 113 个月（中位 106 个月；范围 47-184 个月），20% 的患者发生转移。结论 报告了石蜡切片控制广泛切除后 SGC 局部复发的危险因素，并提出了治疗这些复发病灶的方法。这项研究的结果将有助于指导外科医生应对复发性疾病的医疗和外科难题。初次切除后的头 2 年复发风险最高。
京公网安备 11010802027423号